About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTHâ„¢ or to request a representative, visit YCANTHPro.com
Document Details
Form: 4
Filing Date: March 8, 2019
Document Date: March 6, 2019
Form Description: Statement of changes in beneficial ownership of securities
Filing Group:
3-4-5
Company: Verrica Pharmaceuticals
Filer: Davidson Matt
Filing Formats
View HTML
Download PDF
Download DOC
Download XLS